Researcher
Vigor Van Tendeloo
- Keywords:Medicine
- Disciplines:Innate immunity, Cancer therapy, Hematology, Vaccinology
Affiliations
- Laboratory for Experimental Hematology (LEH) (Research group)
Member
From1 Jan 2019 → 31 Dec 2023 - Vaccine & Infectious Disease Institute (VAXINFECTIO) (Research group)
Member
From1 Oct 2003 → 31 Dec 2018
Projects
1 - 10 of 31
- Preclinical development of a next-generation CAR-T cell therapy for multiple myeloma.From1 Nov 2019 → 31 Oct 2020Funding: Nonprofit institution or equivalents
- Immune effector cell therapy for hematological malignancies with a focus on acute myeloid leukemia and multiple myeloma.From1 Oct 2019 → TodayFunding: FWO fundamental clinical research fellowship
- Vaccine & Infectious Diseases Excellence in Antwerp: Infectious disease prevention, control and management in a One Health policy context (VAX-IDEA).From3 Jul 2019 → 31 Dec 2023Funding: BOF - Methusalem, Fund Recuperation Fiscal Exemption
- Preclinical development of a next-generation CAR-T cell therapy for multiple myeloma.From2 Jul 2019 → 1 Jul 2020Funding: Foundations, funds and other with scientific goal
- Unlocking the TCR repertoire for personalized cancer immunotherapies.From1 Jan 2019 → 31 Dec 2022Funding: FWO Strategic Basic Research Grant
- Improved RNA-based engineering of T lymphocytes with leukemia-specific T cell receptors to redirect their effector functions: towards a clinically safe platform to evaluate efficacy and potential off-target toxicity.From1 Jan 2018 → 31 Dec 2021Funding: FWO research project (including WEAVE projects)
- An interdisciplinary study on the role of the HLA genes and T-cell diversity as risk factors for herpes zoster.From1 Jan 2018 → 31 Dec 2021Funding: FWO research project (including WEAVE projects)
- Harnessing the expression of interleukin-15 and CD56 in immunotherapeutic strategies combating leukemia: a functional and mechanistic characterizationFrom1 Oct 2017 → 12 May 2019Funding: FWO fellowships
- Wilms' tumor 1-specific T cell receptor (TCR) RNA-modified T cells for adoptive immunotherapy of cancer : moving towards clinical application.From1 Jan 2017 → 31 Dec 2018Funding: Foundations, funds and other with scientific goal
- Maximizing the anti-tumor potency of next-generation dendritic cell vaccines by combining interleukin-15 and in situ silencing of programmed-death ligands.From1 Jan 2017 → 31 Dec 2020Funding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 125
- Diagnosing viral infections through T cell receptor sequencing of activated CD8+ T cells(2024)
Authors: Alexandra Vujkovic, My Ha, Tessa de Block, Lida van Petersen, Isabel Brosius, Caroline Theunissen, Sabrina van Ierssel, Esther Bartholomeus, Wim Adriaensen, Guido Vanham, et al.
Pages: 507 - 516 - Lack of functional TCR-epitope interaction is associated with herpes zoster through reduced downstream T cell activation(2024)
Authors: Marlies Boeren, Nicky de Vrij, Sebastiaan Valkiers, Aisha Souquette, Sofie Gielis, Mariia Kuznetsova, Jolien Schippers, Esther Bartholomeus, Johan Van den Bergh, Nele Michels, et al.
Pages: 1 - 18 - In vitro expansion of Wilms’ tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells(2023)
Authors: Donovan Flumens, Maarten Versteven, Stefanie Peeters, Hans De Reu, Diana Campillo Davó, Yannick Willemen, Benson Ogunjimi, Vigor Van Tendeloo, Zwi Berneman, Sébastien Anguille, et al.
Pages: 1 - 18 - Anti-tumor potency of short-term interleukin-15 dendritic cells is potentiated by in situ silencing of programmed-death ligands(2022)
Authors: Maarten Versteven, Donovan Flumens, Diana Campillo Davó, Hans De Reu, Laura Van Bruggen, Vigor Van Tendeloo, Zwi Berneman, Harry Dolstra, Sébastien Anguille, Willemijn Hobo, et al.
- Activation of interferon-stimulated genes following varicella-zoster virus infection in a human iPSC-derived neuronal in vitro model depends on exogenous interferon-α(2022)
Authors: Marlies Boeren, Elise Van Breedam, Marielle Lebrun, Pieter Meysman, Catherine Sadzot-Delvaux, Vigor Van Tendeloo, Geert Mortier, Kris Laukens, Benson Ogunjimi, Peter Ponsaerts, et al.
Pages: 1 - 24 - ESO-ESSO-ESTRO multidisciplinary course in oncology for medical students(2022)
Authors: Nicholas Pavlidis, Radoslaw Madry, Marc Peeters, Sergio Sandrucci, Janina Markowska, Fedro Peccatori, Alberto Costa, Jesper Grau Eriksen, Umberto Ricardi, Richard Poetter, et al.
Pages: 1239 - 1244 - Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon hepatitis B vaccination(2022)
Authors: George Elias, Pieter Meysman, Esther Bartholomeus, Nicolas De Neuter, Nina Keersmaekers, Arvid Suls, Aisha Souquette, Hans De Reu, Marie-Paule Emonds, Evelien Smits, et al.
- Novel insights on MRGPRX2-mediated hypersensitivity to neuromuscular blocking agents and fluoroquinolones(2021)
Authors: Jessy Elst, Marcus Maurer, Vito Sabato, Margaretha Faber, Chris Bridts, Christel Mertens, Michel Van Houdt, Athina Van Gasse, Margo Hagendorens, Vigor Van Tendeloo, et al.
- Advancing RNA-based T-cell receptor redirection of lymphocytes to improve antitumor responses in adoptive T-cell immunotherapy for acute myeloid leukemia(2021)
Authors: Diana Campillo Davó, Vigor Van Tendeloo, Eva Lion
Number of pages: 315 - Characterization of pathogen-specific human CD4 T cells after natural infection and vaccination(2021)
Authors: George Elias, Vigor Van Tendeloo, Benson Ogunjimi
Number of pages: 244
Patents
1 - 1 of 1
Linked dataset
1 - 1 of 1